Category: Cancer

by Emily Henderson, B.Sc.

A functional precision medicine study conducted in Finland demonstrates that treatment selection based on results from drug sensitivity testing of patients’ cells can be clinically useful in patients with aggressive hematological cancers.

Clinicians, researchers and technology experts from the Institute for Molecular Medicine Finland FIMM at the University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center have over the last 10 years developed and tested a functional precision medicine approach to assign therapies to individual cancer patients. Their latest results have just been published in Cancer Discovery, a top-tier journal of the American Association for Cancer Research.

The group has focused on patients with hematological cancers, particularly acute myeloid leukemia (AML), since standard therapies for the advanced forms of these malignancies have a limited effect and the outcome is invariably poor.

Continue reading… “Experts develop a functional precision medicine approach to assign therapies to cancer patients”

Researchers have developed fish-shaped microrobots that are guided with magnets to cancer cells. 

No, it’s not from a science fiction movie or from an episode of a popular kid’s television show. It’s real life. Researchers, in a proof-of-concept study, have made fish-shaped microrobots that are guided with magnets to cancer cells, where a pH change triggers them to open their mouths and release their chemotherapy cargo.

Scientists have previously made microscale (smaller than 100 µm) robots that can manipulate tiny objects, but most can’t change their shapes to perform complex tasks, such as releasing drugs. Some groups have made 4D-printed objects (3D-printed devices that change shape in response to certain stimuli), but they typically perform only simple actions, and their motion can’t be controlled remotely.

Continue reading… “Shapeshifting Microrobots that Fight Cancer on a Cellular Level”

Fish-shaped microrobots are guided with magnets to cancer cells, where they open their mouths to release their chemotherapy cargo.

Bu Katie Cottingham

Delivering drugs directly to cancer cells could help reduce chemotherapy’s unpleasant symptoms.

Chemotherapy successfully treats many forms of cancer, but the side effects can wreak havoc on the rest of the body. Delivering drugs directly to cancer cells could help reduce these unpleasant symptoms. Now, in a proof-of-concept study, researchers reporting in ACS Nano made fish-shaped microrobots that are guided with magnets to cancer cells, where a pH change triggers them to open their mouths and release their chemotherapy cargo.

Continue reading… “Shape-Shifting Microrobots Deliver Drugs to Cancer Cells”

By Jessica Brown Anchor/Reporter

A vaccine with the potential to revolutionize cancer treatment is being tested in Boston. The customized vaccines are intended to help the body’s immune system target an individual’s tumor.

Heather Walker, a wife, mother and Boston Celtics executive, is participating in the clinical trial. In July, doctors discovered a fast-growing tumor in her brain, called glioblastoma. Advertisement

The rare and aggressive form of cancer is diagnosed in about 13,000 adults in the U.S. each year. More than 93% of patients die within 5 years and the average survival is about 15 months.

“Historically, when a glioblastoma was diagnosed, patients were often referred to a palliative care, a kind of hospice situation because treatment was not able to be effective,” said Dr. David Reardon, clinical director of the Center for Neuro-Oncology at the Dana Farber Cancer Institute. 

Continue reading… “A revolutionary clinical trial is testing customized vaccines that target cancerous tumors”

A decade ago, genome sequencing revealed a big surprise: about 50 percent of human cancers are linked to mutations in what are known as epigenetic regulators, which control the activity of genes.

In a new study in Cell Chemical Biology, a team of scientists led by Oliver Bell from USC and Stephen V. Frye from the University of North Carolina at Chapel Hill developed a new drug-like molecule that can counteract the effects of mutated epigenetic regulators, which are known to drive certain types of cancer including lymphoma.

Continue reading… “New Drug-Like Molecule Counteracts Epigenetic Drivers of Cancer”

Image from scanning electron microscope, which shows selenium nanoparticles, ejected during femtosecond laser ablation of bulk selenium target in distilled water. This image captured the melted “tails” of nanoparticles, which emerge during their ejection from the bulk target.

EVONANO, a multidisciplinary project, brings together experts in artificial intelligence, computer science, microfluidics, modeling, and medicine to offer a novel method for cancer treatment research. The new software enables scientists to grow virtual tumors and use artificial intelligence (AI) to design nanoparticles to treat them.

According to Phys.org, growing and treating virtual tumors has become an essential step in developing new therapies for cancer as it allows scientists to optimize the design of nanoparticle-based drugs before testing them in the laboratory and on the patients.

Continue reading… “Cancer Treatment: New Software Uses Artificial Intelligence to Grow, Treat Virtual Tumors”

Combination therapy against anti-PD-1-resistant lung cancer. A combination of anti-PD-1 antibodies and stimulator of an interferon gene (STING)-loaded lipid nanoparticles (STING-LNP) had the maximum effect in reducing metastases (black regions) on lungs (pink tissue; far right). STING-lipid nanoparticles alone had a better effect (center right) than anti-PD-1 antibodies (center left), which were as effective as the control saline solution.

A specially designed lipid nanoparticle could deliver immune-signaling molecules into liver macrophage cells to overcome resistance to anti-tumor immunotherapy.

After intravenous injection into mice, STING-lipid nanoparticles (red) transported through blood vessels(green) accumulate in the liver (Takashi Nakamura, et al. Journal for ImmunoTherapy of Cancer. July 2, 2021).

Hokkaido University scientists and colleagues in Japan have found a way that could help some patients overcome resistance to an immunotherapy treatment for cancer. The approach, proven in mice experiments, was reported in the Journal for Immunotherapy of Cancer.

Continue reading… “New nano particles suppress resistance to cancer immunotherapy”

Summary: A newly identified gene therapy pathway has the potential to protect us against dementia and cancer, researchers report.

Source: University of Sheffield

Researchers from the University of Sheffield have discovered a new gene therapy pathway that has uncovered an important regulatory mechanism to keep our genome healthy. This pathway has the potential to protect us against serious life-limiting diseases such as cancer and dementia.

Cancer and neurodegeneration are two major health challenges currently affecting the population, and they constitute two sides of the same coin – one is caused by uncontrolled cell proliferation due to genome damage, and the other is caused by excessive genome damage that causes cell death. This new pathway impacts both and offers new therapeutic opportunities to help the fight against disease.

Published in Nature Communications, the research found that when cells in our body read DNA to build proteins, they often make mistakes that can damage our genome, causing disease such as cancer and dementia.

However, by investigating how cells fix damage in the DNA to keep us healthy, scientists have discovered the benefits of three proteins working together as a team. The three proteins, called USP11, KEAP1 and SETX, receive instructions from their coach to direct their function in space and time with remarkable harmony, to keep our DNA healthy.

Continue reading… “New Gene Therapy Pathway Could Protect Us From Cancer and Dementia”

PHILADELPHIA—Chimeric antigen receptor (CAR) T cell therapy, which uses engineered T cells to treat certain types of cancers, has often been a challenging approach to treating solid tumors. CAR T cells need to recognize a specific target on cancer cells to kill them. However, cancer cells do not always have the target, or they find ways to hide the target and stay invisible to CAR T cell attack. A new study from Penn Medicine, published online in Cell, demonstrates that RN7SL1, a naturally occurring RNA, can activate the body’s own natural T cells to seek out the cancer cells that have escaped recognition by CAR T cells. This may help improve efforts to treat solid tumors, which represent most human cancers.

“CAR T cells typically are like lone soldiers without backup. However, if given the right tools, they can kickstart the body’s own immune system and give them help against the cancer cells missed with CAR T cells alone,” said co-lead author Andy J. Minn, MD, PhD, a professor of Radiation Oncology in the Perelman School of Medicine at the University of Pennsylvania and director of the Mark Foundation Center for Immunotherapy, Immune Signaling, and Radiation at Penn.

Continue reading… “Engineering CAR T Cells to Deliver Endogenous RNA Wakes Solid Tumors to Respond to Therapy”

ONE of the most challenging aspects of cancer treatment is the huge variety of different tumours that can occur with each one potentially requiring a different solution because unfortunately, one drug does NOT fit all.

In addition, another major issue of many current drugs is their poor selectivity towards cancers resulting in problems such as normal tissue toxicity, severe side effects and the development of drug resistance.

Now, a team of scientists at the University of Huddersfield is researching how to combat these challenges by using “self-assembled” drugs and although the research is in its very early stages, they’ve already had a breakthrough.

Continue reading… “Cancer therapy breakthrough in vitro using self-assembled drugs”